newsfilter.io

Healthcare Earnings Report — 2026-06-26 to 2026-08-10

Report generated: 2026-08-10 16:06:25 EDT

Overview

Companies reported: 402 (2026-06-26 - 2026-08-10). The healthcare sector delivered a mixed but generally positive earnings picture, characterized by strong revenue growth driven by commercial product launches and regulatory milestones, which offset significant one-time charges and integration costs for several major players. Established commercial entities like Eli Lilly (LLY), Alnylam Pharmaceuticals (ALNY), and Insmed (INSM) led the performance with double-digit to triple-digit revenue surges, while clinical-stage firms focused on extending cash runways through capital raises and strategic partnerships. Despite these top-line gains, net income results were divergent, with some companies reporting substantial GAAP losses due to non-cash impairments, acquisition charges, or integration expenses, even as they revised full-year guidance upward.

Leaderboard

Top 5 by Revenue Growth (YoY)

# Company Ticker Revenue Growth YoY Revenue
1 Insmed Inc. INSM 296% $425.5 million
2 Astrana Health Inc. ASTH 49% $972.5 million
3 Halozyme Therapeutics Inc. HALO 48% $481.0 million
4 Eli Lilly & Co. LLY 48% $23.0 billion
5 Axsome Therapeutics Inc. AXSM 46% $218.4 million

Note: Axsome Therapeutics (46%) and Halozyme (48%) are listed based on their reported growth rates; Halozyme's growth is primarily driven by a 50% increase in royalty revenue.

Top 5 by Net Income Growth (YoY)

# Company Ticker Net Income Growth YoY Net Income
1 Nutex Health NUTX 3,100% $112.6 million
2 BioLife Solutions BLFS N/A $45.1 million
3 Viatris VTRS N/A $(119) million
4 BioMarin Pharmaceutical BMRN N/A $45 million
5 Canopy Growth CGC N/A $(14.6) million

Net income growth rates for BioLife Solutions, Viatris, BioMarin Pharmaceutical, and Canopy Growth are not listed as the summaries provide absolute values or percentage changes in revenue/EBITDA rather than a direct YoY net income growth percentage; BioLife Solutions swung from a loss to a profit, Viatris and BioMarin reported declines, and Canopy Growth narrowed a loss.

Themes

  • Biotechnology firms are prioritizing cash runway extension through substantial equity and debt financings to fund late-stage clinical trials and regulatory submissions, with many companies securing multi-year liquidity to reach potential commercialization or pivotal data readouts.
  • Commercialization momentum is evident across several drug manufacturers and biotechs, where net product sales growth is offsetting rising R&D and SG&A expenses, leading to narrowed losses or a return to profitability for companies with approved therapies.
  • Mergers and acquisitions activity remains a dominant theme, with multiple companies announcing definitive agreements for strategic consolidation, such as acquisitions by larger pharmaceutical firms or mergers of equals to expand pipeline portfolios and diversify revenue streams.
  • Companies are actively managing balance sheet leverage and capital structure through share repurchase programs, debt refinancing, and the divestiture of non-core assets to optimize financial profiles and fund strategic priorities.
  • Operational efficiency is a key driver, with numerous firms executing workforce reductions, restructuring plans, and cost-saving initiatives to reduce operating expenses and improve adjusted EBITDA margins despite inflationary pressures.
  • Regulatory milestones are accelerating, with a high volume of companies targeting FDA approvals, PDUFA dates, and BLA submissions in the second half of 2026, which are expected to serve as major catalysts for stock performance and commercial launch readiness.
  • Revenue guidance revisions reflect a mix of headwinds and tailwinds, including pricing pressures, tariff impacts, and demand softness in specific geographies, contrasted by strong growth in international markets and new product launches.
  • Strategic partnerships and collaboration agreements are providing critical non-dilutive funding and milestone payments, particularly for companies in the pre-revenue or clinical development stages, helping to sustain operations without immediate equity dilution.
  • Medical device and diagnostic companies are leveraging technology integration, such as AI-driven tools and automation, to enhance product value propositions, improve reimbursement rates, and drive organic growth in installed bases.
  • The sector is experiencing a divergence in financial performance, with established commercial entities delivering strong cash flow and earnings growth while clinical-stage companies focus on extending cash runways and achieving key clinical milestones to de-risk their pipelines.

Market Outlook & Trends

  • Revenue growth is being driven by commercial product launches and strong demand for established therapies, with Axsome Therapeutics (AXSM) citing 46% revenue growth from AUVELITY and SYMBRAVO, while Insmed (INSM) reported a 296% surge in BRINSUPRI sales and Alnylam Pharmaceuticals (ALNY) saw AMVUTTRA revenues double to $1.01 billion.
  • Several companies have revised full-year revenue guidance upward, including RadNet (RDNT) raising imaging center guidance, Natera (NTRA) increasing its annual revenue midpoint by $100 million, and Viatris (VTRS) raising total revenue and adjusted EPS guidance despite supply disruptions at its Nashik facility.
  • Conversely, demand headwinds and execution challenges have led to guidance reductions for some, with Quanterix (QTRX) lowering 2026 revenue guidance due to market softness, QuidelOrtho (QDEL) revising forecasts downward citing demand weakness in China, and Canopy Growth (CGC) noting supply chain and regulatory risks affecting U.S. re-entry.
  • Backlog and capacity commentary indicates strong momentum in specific segments, such as Varex Imaging (VREX) expecting continued momentum in cargo and vehicle inspection systems, and Sotera Health (SHC) reporting a backlog of $7.8 billion with a 1.12x book-to-bill ratio.
  • Pricing and cost expectations are mixed, with companies like Envista (NVST) and Baxter International (BAX) citing tariff refunds and inflationary pressures impacting margins, while others like Theravance Biopharma (TBPH) and aTyr Pharma (ATYR) are executing strategic restructurings to reduce operating expenses by significant margins.
  • M&A activity is a key theme, with multiple companies announcing definitive agreements to be acquired, including Theravance Biopharma (TBPH) by Zymeworks (ZYME), Apogee Therapeutics (APGE) by AbbVie (ABBV), and Crinetics Pharmaceuticals (CRNX) by Vertex Pharmaceuticals (VRTX), alongside major strategic acquisitions like BioMarin's (BMRN) purchase of Amicus and Vertex's acquisition of Crinetics.
  • Liquidity and cash runway remain a primary focus for clinical-stage biotechs, with many companies raising capital to extend operations into 2028 or 2029, such as Entera Bio (ENTX) securing $275 million to fund through 2030, and Dyne Therapeutics (DYN) raising $405 million to reach Q2 2028.
  • Regulatory milestones are driving near-term catalysts, with multiple companies targeting PDUFA dates in late 2026, including Intellia Therapeutics (NTLA) for lonveloz, UroGen Pharma (URGN) for UGN-103, and Regeneron (REGN) for cemdisiran, while others like Vaxcyte (PCVX) and Viatris (VTRS) face risks from regulatory delays or litigation.
  • Risks identified by management include geopolitical tensions affecting supply chains and trial sites, as noted by Lineage Cell Therapeutics (LCTX) regarding Israel, and specific regulatory hurdles such as CMS reimbursement changes impacting Sanuwave (SNWV) and Medicare Advantage Star Ratings affecting Humana (HUM) and Clover Health (CLOV).
  • Strategic pivots and portfolio optimization are evident, with companies like Cytokinetics (CYTK) and Arcus Biosciences (RCUS) discontinuing certain programs to focus on core assets, while others like Intuitive Surgical (not listed but implied by context of device growth) and Boston Scientific (BSX) continue to invest heavily in R&D and acquisitions to drive long-term growth.

Key Numbers

  • Health Catalyst (HCAT) reported a 13% year-over-year revenue decline to $70.487 million, while GAAP net loss narrowed 1% to $40.537 million and Adjusted EBITDA rose 6% to $9.919 million.
  • Viatris (VTRS) posted 5% year-over-year revenue growth to $3.8 billion, with Adjusted EBITDA increasing 10% to $1.2 billion and Adjusted EPS rising 11% to $0.69.
  • Insmed (INSM) saw total company revenues surge 296% year-over-year to $425.5 million, driven by a 49% sequential increase in BRINSUPRI sales to $309.2 million, while net loss narrowed significantly to $13.2 million from $321.7 million in the prior year.
  • Alnylam Pharmaceuticals (ALNY) recorded a 67% year-over-year revenue increase to $1,290.9 million, with net product revenues up 74% to $1,172.1 million, resulting in a GAAP net income turnaround to $164.5 million from a $72.2 million loss.
  • Incyte (INCY) reported total revenue growth of 38% year-over-year to $1.67 billion and total net sales growth of 40% to $1.49 billion, with GAAP diluted EPS at $2.81 and Non-GAAP diluted EPS at $3.09.
  • Regeneron (REGN) achieved a 17% year-over-year revenue increase to $4.3 billion, driven by a 51% surge in collaboration revenue to $2.2 billion, while Non-GAAP net income grew 8% to $1.5 billion.
  • Vertex Pharmaceuticals (VRTX) posted 12% year-over-year revenue growth to $3.33 billion, with GAAP net income increasing to $1.1 billion from $1.0 billion in the prior year quarter.
  • Eli Lilly (LLY) reported a 48% year-over-year revenue surge to $23.0 billion, with net income rising 25% to $7.1 billion ($7.94 per share) and non-GAAP net income increasing 32% to $7.5 billion ($8.38 per share).
  • Bristol Myers Squibb (BMY) saw total revenues rise 6% year-over-year to $12.973 billion, with GAAP EPS reaching $1.62 compared to $0.64 in the prior year.
  • AbbVie (ABBV) reported a 10.2% year-over-year revenue increase to $16.990 billion, while adjusted diluted EPS grew 22.9% to $3.65.

Outliers

  • Viatris (VTRS) reported a GAAP net loss of $119 million driven by a $177.8 million non-cash charge related to the Tyrvaya rights sale, despite raising full-year guidance.
  • BioMarin (BMRN) saw GAAP net income fall 81% to $45 million due to Amicus acquisition integration costs, interest expense, and amortization, even as revenue rose 20%.
  • Merck (MRK) recorded a GAAP net loss of $1.3 billion and Non-GAAP net loss of $330 million, significantly impacted by $2.31 per share in acquisition charges for Terns Pharmaceuticals and higher amortization.
  • Pfizer (PFE) reported a GAAP net loss of $0.04 per share driven by $4.3 billion in non-cash intangible asset impairments, though it raised its full-year revenue guidance midpoint.

25 most recent Healthcare earnings

  1. IBIOHealthcare

    iBio — Fiscal Year 2026 Earnings Summary

    IBIO INC

    Revenue declined to $0.1 million from $0.4 million in fiscal 2025, while net loss widened to $33.0 million from $18.4 million due to a $19.6 million increase in R&D expenses and a $5.0 million impairment of IBIO-101 assets. Cash runway extended into fiscal year 2028 following significant capital raises, including a $26 million private placement in January 2026 and a public offering with up to $100 million in potential gross proceeds, raising total cash and investments to $88.0 million. Pipeline advancement includes moving IBIO-600 into multiple ascending dose escalation for Phase 1, advancing IBIO-610 into IND-enabling studies, and selecting IBIO-800 as a development candidate with in-licensed rights to the AstralBio amylin receptor program. Leadership strengthened with the appointment of Molly Carr, M.D., as Chief Medical Officer and Elizabeth Stoner, M.D., to the Board, alongside the establishment of an Open Market Sale Agreement for up to $100 million of common stock.

  2. HQYHealthcare

    HealthEquity — Second Quarter Ended July 31, 2026 Earnings Summary

    HEALTHEQUITY INC

    Revenue grew 8% year-over-year to $350.7 million, while net income rose 10% to $65.6 million ($0.78 per share) and non-GAAP net income increased 15% to $103.8 million ($1.24 per share). Management raised fiscal 2027 guidance, projecting full-year revenues of $1.411–$1.421 billion, net income of $242–$248 million, and Adjusted EBITDA of $628–$636 million. Total HSA assets expanded 14% year-over-year to $37.9 billion, with new HSAs from sales up 24% to 202,000 and total accounts reaching a record 10.7 million. The company returned $108.1 million to shareholders via stock repurchases in the quarter, with $948.4 million remaining authorized under the program.

  3. VEEVHealthcare

    Veeva Systems — Fiscal 2027 Second Quarter Earnings Summary

    VEEVA SYSTEMS INC

    Total revenue reached $928.0 million, up 18% year-over-year, with net income rising 37% to $273.4 million and non-GAAP net income increasing 16% to $387.4 million. Management raised full-year 2027 guidance, projecting total revenue of $3,682–$3,687 million and non-GAAP net income per share of approximately $9.21, following results that exceeded all prior guidance metrics. The company acquired Copli and repurchased $472.7 million of common stock during the first six months of the fiscal year, while cash and cash equivalents grew to $1,812.0 million. Strategic momentum continues with Vault CRM securing commitments from five additional top 20 biopharmas, Veeva Safety surpassing 100 customers, and Veeva Falcon on track for initial go-lives in 2026.

  4. AHealthcare

    Agilent Technologies — Third Quarter Fiscal Year 2026 Earnings Summary

    AGILENT TECHNOLOGIES INC

    Q3 2026 revenue reached $1.88 billion, up 8.1% reported and 7.3% core year-over-year, while GAAP net income rose 8% to $362 million and Non-GAAP net income increased 18% to $459 million. Fiscal 2026 guidance was raised to $7.49 billion–$7.51 billion in revenue and $6.18–$6.21 in Non-GAAP EPS, with Q4 revenue expected between $1.98 billion and $2.0 billion. Operating margins expanded significantly, with GAAP margin at 23.6% (up 290 bps YoY) and Non-GAAP margin at 28.3% (up 320 bps YoY), including an $17 million net benefit from tariff refunds. Nine-month investing cash outflows totaled $1.2 billion, primarily driven by $950 million in payments for business and intangible asset acquisitions, while financing activities included $295 million in stock repurchases and $216 million in dividends.

  5. ONCHealthcare

    BeOne Medicines Ltd. — Six Months Ended June 30, 2026 Earnings Summary

    BEONE MEDICINES LTD

    Total R&D expenses increased to $1,153.5 million for the six months ended June 30, 2026, from $1,006.8 million in the prior year period, driven by higher internal and external costs. R&D spending shifted toward new programs, with significant increases allocated to Tacabrutideg ($44.3M vs. $26.9M), BGB-43395 ($22.7M vs. $9.9M), and BGB-B2033 ($6.6M vs. $1.1M), while expenses for BRUKINSA, TEVIMBRA, and BEQALZITM declined. Collaboration project expenses rose to $83.5 million from $47.6 million year-over-year, reflecting increased activity in joint development arrangements. The company filed its 2026 Interim Report with the STAR Market on August 26, 2026, noting material accounting differences between PRC GAAP and U.S. GAAP regarding share-based compensation, lease presentation, and the treatment of upfront cash from royalty transfers.

  6. ELMDHealthcare

    Electromed, Inc. — Fiscal 2026 Earnings Summary

    ELECTROMED INC

    Net revenue grew 15.3% year-over-year to $73.8 million for full-year FY 2026, with net income rising 50.7% to $11.3 million ($1.30 diluted EPS) compared to $7.5 million ($0.85 diluted EPS) in FY 2025. Operating income increased 43.7% to $13.9 million for the full year, driven by gross margin expansion to 78.5% and a 370 basis point increase in operating margin over FY 2025. Direct homecare revenue led growth with a 16.3% year-over-year increase to $66.6 million, supported by higher sales representative productivity exceeding the $1.1 million target. The company repurchased $3.9 million of common stock during FY 2026 and reported a strong balance sheet with $20.5 million in cash and no debt as of June 30, 2026. Electromed marked its 15th consecutive quarter of year-over-year revenue and profit growth, with strategic investments focused on sales force expansion and bronchiectasis market development.

  7. HINDHealthcare

    Vyome Holdings — Second Quarter 2026 Earnings Summary

    VYOME HOLDINGS INC

    Cash and stockholders' equity increased to $7.9 million and $7.3 million respectively as of June 30, 2026, from $5.0 million and $3.8 million at year-end 2025, while maintaining a debt-free capital structure. Revenues and gross profit declined significantly for the six months ended June 30, 2026, falling to $58,546 and $28,303 compared to $248,535 and $178,654 in the prior period, with net loss widening to $1.7 million from $602,732. VT-1953 Phase 2 data showed statistically significant improvements in malodor and lesion pain with no adverse events, and the company in-licensed two new JAK inhibitor assets from Impetis Biosciences while securing a Chinese patent for the program. Management plans to incorporate FDA feedback received in Q2 2026 regarding the pivotal study strategy for malignant fungating wounds, prioritizing non-dilutive capital methods to advance the pipeline.

  8. AVXLHealthcare

    Anavex Life Sciences — Third Fiscal Quarter 2026 Earnings Summary

    ANAVEX LIFE SCIENCES CORP

    Reported net income of $7.8 million ($0.08/share) for Q3 2026, a significant turnaround from a $13.2 million loss in the prior year period, driven primarily by the reversal of $17.4 million in stock-based compensation expenses associated with employee terminations. Cash reserves increased to $118.3 million as of June 30, 2026, with management projecting these funds will support operations through mid-to-late fiscal 2028; the company holds no debt and total liabilities of $7.7 million. Strategic outlook includes filing outstanding 10-Q reports to regain Nasdaq compliance, submitting an IND for Fragile X syndrome in September, and advancing Phase 3 studies for Rett syndrome and Alzheimer's disease following FDA feedback. Management emphasized a methodical, financially disciplined approach to aligning U.S. clinical development strategies with the FDA, while noting ongoing risks related to regulatory compliance, litigation, and capital raising.

  9. COSMHealthcare

    Cosmos Health — Q2 2026 Earnings Summary

    COSMOS HEALTH INC

    Q2 2026 revenue reached $18.99 million (up 28.8% YoY) with adjusted revenue of $19.32 million (up 31.0% YoY); adjusted gross margin expanded 165 basis points to 9.54%, while operating expenses grew at roughly half the rate of revenue. Net loss widened to $6.09 million in Q2 2026 compared to $2.83 million in the prior year, primarily driven by $2.65 million in non-cash fair value adjustments on financing arrangements; adjusted EBITDA improved to ($1.13 million) from ($1.31 million). Management projects a second-half seasonality similar to the prior year and targets $75 million in annualized revenue, with the U.S. market expected to become a principal growth engine supported by local manufacturing and new product launches. Strategic capital allocation includes a $5.0 million share repurchase program (authorizing $513,000 in Q2 repurchases), the expiration of 4.87 million Series B warrants eliminating 38% of overhang, and a letter of intent to acquire Doc Pharma S.A. Balance sheet strength improved with total liabilities decreasing 13.3% to $40.79 million and stockholders' equity rising 12.2% to $20.67 million, while inventory decreased 21.8% despite nearly 30% revenue growth.

  10. PFSAHealthcare

    Profusa — Q2 2026 Earnings Summary

    PROFUSA INC

    Net loss widened to $(8.8) million for the three months ended June 30, 2026, compared to $(2.3) million in the prior year period, with a six-month loss of $(12.2) million versus $(5.1) million; cash on hand stood at $719,000 with total liabilities of $28.2 million. Debt and liability holders executed $10.7 million in Series A Convertible Exchange Agreements, converting $4.57 million into Preferred Stock, while the company borrowed an additional $650,000 to fund near-term working capital needs. The company anticipates sufficient working capital for the near term and expects stockholders' equity to reach $28.4 million following the execution of the Option Agreement to acquire G3 Vision Labs, Inc. A 4:1 reverse stock split effective August 18, 2026, was executed to meet Nasdaq listing requirements, and auditors are expected to finalize G3's 2024 and 2025 financial statements by mid-September.

  11. JAGXHealthcare

    Jaguar Health — Second Quarter 2026 Earnings Summary

    JAGUAR HEALTH INC

    Total net revenue fell 59% year-over-year to $1.225 million, driven by a 60% decline in product revenue to $1.182 million due to the transition of U.S. commercial rights to Future Pak, while operating loss narrowed 5% to $7.597 million. Net loss attributable to common stockholders increased 22% to $12.690 million, primarily due to a $3.504 million loss on debt extinguishment and $1.9 million in fair value adjustments, though loss per share decreased 96% to $(15.68) following share consolidation. Strategic shifts include the dissolution of the Jaguar/Napo Sales and Marketing Group, reducing sales and marketing expenses to $5,000, and the establishment of a cost-plus licensing agreement with Future Pak for Mytesi and Canalevia-CA1. Crofelemer development remains on track with a clinical package for the MVID New Drug Application expected by year-end 2026, targeting a Q2 2027 submission, alongside a $3.3 million R&D spend focused on lyophilization progress. No new capital return, M&A, or specific financial guidance changes were announced; the company continues to recognize $43,000 in license revenue from a European partner with $468,000 in deferred revenue.

  12. ARAYHealthcare

    Accuray — Fiscal 2026 Earnings Summary

    ACCURAY INC

    Total net revenue declined 12% YoY to $401.9 million for fiscal 2026 and 21% YoY to $100.9 million in Q4, driven by a 27% and 42% drop in product revenue respectively, partially offset by 4% and 6% service revenue growth. GAAP net loss widened to $49.2 million ($0.40/share) for the full year compared to $1.6 million in the prior year, while Q4 GAAP net loss narrowed to $1.9 million; gross margin improved to 34.8% in Q4 despite lower full-year margins of 27.7%. Management announced a financing transaction with TCW Asset Management to strengthen liquidity and reduce leverage, while delivering over $20 million in cost and margin improvements through its transformation plan. The company is not providing formal revenue or Adjusted EBITDA guidance for fiscal 2027 due to geopolitical uncertainty, tariff impacts, and macroeconomic conditions, though it anticipates continued service revenue growth and operating expense discipline. Order backlog decreased 27% YoY to $312.5 million, with gross product orders falling 42% in Q4 and 33% for the full year, while long-term debt increased to $146.4 million.

  13. SRXHHealthcare

    SRX Global Inc. — Fiscal Third Quarter 2026 Earnings Summary

    SRX GLOBAL INC

    Net sales rose 27% year over year to $3.4 million, while operating loss narrowed 63% year over year to $3.2 million and net loss from continuing operations improved 40% year over year to $4.1 million. Completed the acquisition of EMJX on June 16, 2026, to expand digital-asset treasury capabilities, with capital allocation prioritized toward Halo's growth and selective minority investments. Declared a fully funded one-time cash dividend of $0.05 per share and approved a 10 million share repurchase program, following a one-for-sixty reverse stock split effective July 6, 2026. Maintained a highly liquid balance sheet with $36.7 million in cash, no outstanding debt, and a Net Asset Value of $3.22 per share, exceeding preliminary estimates.

  14. INBSHealthcare

    Intelligent Bio Solutions — Fiscal 2026 Earnings Summary

    INTELLIGENT BIO SOLUTIONS INC

    Revenue increased 38% year-over-year to $4.22 million, while gross profit rose 64% to $2.05 million, expanding gross margin by 778 basis points to 48.63%. Net loss widened to $12.43 million from $10.57 million in fiscal 2025, though cash and cash equivalents grew to $3.99 million and all notes payable were eliminated. The FDA 510(k) submission remains on track for the second half of calendar 2026, with management targeting U.S. market entry in the multi-billion-dollar drug screening sector. Strategic manufacturing transition to Syrma Johari is underway to improve cost structure, supported by a 22% growth in the reader installed base to 1,886 units and a 35% increase in consumable sales. Fiscal 2027 priorities focus on sustaining margin expansion, accelerating commercial growth, and advancing the regulatory program, following a 1-for-10 reverse stock split completed in December 2025.

  15. IRIXHealthcare

    Iridex Corporation — Second Quarter 2026 Earnings Summary

    IRIDEX CORP

    Total revenue declined 7% year-over-year to $12.6 million, driven by a 19% drop in Retina product sales to $6.5 million, partially offset by a 19% year-over-year increase in Cyclo G6 revenue to $3.9 million. The company reaffirmed full-year 2026 revenue guidance of $51 million to $53 million and adjusted operating expense guidance of $19 million to $19.5 million, while reporting a net loss of $1.3 million and positive operating cash flow. Strategic restructuring efforts are underway, including relocating headquarters to a lower-cost facility and transferring production to contract manufacturers, with management citing these measures as key to achieving sustained long-term profitability. Future outlook remains focused on improving retina performance through advancing international regulatory approvals and the Pascal platform, despite temporary headwinds from commercial transitions in the Middle East and reduced sell-through in China.

  16. XAIRHealthcare

    Beyond Air — Q2 2026 Earnings Summary

    BEYOND AIR INC

    Revenue remained flat at $1.8 million year-over-year, while gross margin expanded to 13% from 9%; net loss widened to $7.9 million ($11.00/share) from $7.7 million ($30.67/share) despite a $1.1 million reduction in R&D expenses. Reaffirmed 2026 revenue guidance of $8 million (excluding second-gen LungFit PH) and 2027 guidance of $16-$18 million, anticipating over 110% growth driven by the new system pending FDA approval expected in H2 2026. Secured up to $30.1 million in subsequent financing ($10.2 million upfront, $20.0 million contingent on warrant exercises), with $10 million of the contingent portion tied to second-generation system approval. Advanced commercial strategy by securing a third major U.S. GPO agreement expanding reach to nearly 2,000 hospitals and regaining compliance with Nasdaq's minimum bid price requirement. Transitioning fiscal year-end from March 31 to December 31 effective December 31, 2026, while the second-generation LungFit PH system remains under FDA review with international submissions on track.

  17. DCGOHealthcare

    DocGo — Second Quarter 2026 Earnings Summary

    DOCGO INC

    Q2 2026 total revenue declined to $73.4 million from $80.4 million in Q2 2025; excluding the wind-down of migrant-related programs, revenue increased 19% year-over-year, driven by 15% growth in medical transportation and 78% growth in mobile health services. Full-year 2026 revenue guidance narrowed to $305-$310 million (excluding Hicuity Health contributions), while adjusted EBITDA guidance was lowered to ($17-$22) million from a prior range of ($5-$10) million. Management announced a definitive agreement to acquire 100% of virtual care provider Hicuity Health, which will assume approximately $52 million in existing indebtedness and provide a combined entity with greater liquidity and cost synergies. The company faces significant liquidity risks, with unrestricted cash declining to $25.2 million as of June 30, 2026, and management highlighted ongoing risks regarding its ability to maintain a Nasdaq listing and continue as a going concern. Despite a net loss of $18.0 million and adjusted EBITDA of ($6.3) million for the quarter, management expects to exit 2026 at a profitable run rate and achieve positive adjusted EBITDA heading into 2027.

  18. NDRAHealthcare

    ENDRA Life Sciences — Second Quarter 2026 Earnings Summary

    ENDRA LIFE SCIENCES INC

    Reported net income of approximately $160,000 for Q2 2026, a significant turnaround from a $1.2 million net loss in the same period of 2025, driven primarily by $1.6 million in other income from digital asset gains. Entered into a definitive merger agreement with Noble Africa, expected to close in Q4 2026, which will result in the company renaming to Noble Africa Inc. and gaining exposure to Renergen's Virginia Gas Project. Strengthened balance sheet with total assets rising to $7.9 million and total stockholders' equity increasing to $6.3 million as of June 30, 2026, supported by a $3.8 million private placement completed in May 2026. Operating expenses increased to $1.5 million year-over-year, though R&D and sales/marketing expenses decreased 39% and 92% respectively, while cash used in operations declined to $0.9 million from $1.1 million in the prior year. Future outlook hinges on satisfying closing conditions for the merger and a concurrent private placement expected to generate approximately $50 million in gross proceeds, though risks remain regarding regulatory approvals and digital asset volatility.

  19. AIDXHealthcare

    20/20 BioLabs — Second Quarter 2026 Earnings Summary

    20/20 BIOLABS INC

    Q2 2026 total revenue rose 36.5% year-over-year to $0.7 million, driven by a 47.1% increase in OneTest™ revenue to $0.7 million, while gross margin expanded 11.2 percentage points to 41.7% despite operating expenses increasing to $1.5 million. The company strengthened its balance sheet by eliminating all convertible note debt, raising $1.0 million in additional Series E capital (totaling $6.0 million for H1 2026), and turning stockholders' equity positive to $1.62 million. State-funded firefighter screening programs in Vermont and Maryland are projected to generate over $1.0 million in revenue through 2026, with management expecting to test more than 35,000 firefighters to support future regulatory and reimbursement strategies. Strategic expansion includes a retail pilot with Giant Food for OneTest™ for Longevity, new commercial orders from BodyMetRX and 29 new accounts, and a purchase agreement to expand access within the U.S. Intelligence Community.

  20. IVFHealthcare

    INVO Fertility — Q2 2026 Earnings Summary

    INVO FERTILITY INC

    Total revenue increased 17% year-over-year to $2,175,485, driven by a full-quarter contribution from the Family Beginnings acquisition and organic growth; net income improved to $0.9 million from a $3.6 million loss in the prior year period. Clinic-Level Adjusted EBITDA rose to approximately $333,000 in Q2 2026 compared to $164,000 in Q1 2026, while consolidated Adjusted EBITDA remained negative at $(1.0) million versus $(0.6) million in Q2 2025. Strategic milestones include the conversion of the Birmingham clinic to a wholly owned subsidiary in June 2026, generating a $2.5 million gain on remeasurement, and the recognition of no losses from discontinued operations compared to $2.1 million in losses related to NAYA Therapeutics in the prior year. Management outlined a future outlook focused on organic growth and disciplined acquisitions of established, profitable fertility practices to leverage shared infrastructure, with cash on hand standing at $3.7 million as of June 30, 2026.

  21. NXGLHealthcare

    NEXGEL — Second Quarter 2026 Earnings Summary

    NEXGEL INC

    Q2 2026 revenue totaled $3.69 million with a net loss of $2.87 million, which included $756,554 in BioNX intangible asset amortization, $273,710 in one-time transaction expenses, and $144,495 in costs related to the strategic SilverSeel recall. Management anticipates slower-than-anticipated integration and revenue ramp but expects opportunities to emerge in the second half of the year, driven by a hospital channel launch and higher gross margins. The company plans to resolicit shareholder approval for an increase in authorized shares and reverse split authority as standalone proposals in late September 2026, following insufficient support in the previous proxy solicitation. Strategic initiatives include the formation of the BioNX Surgical division, the transfer of manufacturing technology to Sequence Life Science in San Antonio, and the launch of the BioNX Regenerative Eye Health & Aesthetics platform. BioNX Surgical backlog stands at approximately $795,000, and restricted cash of $710,000 previously held with ATW Partners was released and returned to the company after the quarter ended.

  22. NSPRHealthcare

    InspireMD — Second Quarter 2026 Earnings Summary

    INSPIREMD INC

    Total revenue declined 0.4% year-over-year to $1.77 million for the quarter, driven by negative U.S. revenue of $351,000 due to a voluntary recall, while international revenue rose 21% to $2.12 million; six-month revenue increased 56.3% to $5.17 million. The company reported a net loss of $14.3 million ($0.17 per share) for the quarter, compared to $13.2 million ($0.26 per share) in 2025, with gross loss of $774,000 including $612,000 in inventory impairment and $734,000 in recall-related credits. Cash and cash equivalents plus marketable securities decreased to $30.4 million as of June 30, 2026, from $54.2 million at year-end 2025, amid stated substantial doubt regarding the ability to continue as a going concern. Management anticipates FDA decisions later in 2026 and expects savings actions to generate approximately $9 million in annual savings, while appointing a new SVP of Global Sales and Marketing to support a U.S. re-launch pending regulatory approvals.

  23. PRPOHealthcare

    Precipio — Q2-2026 Earnings Summary

    PRECIPIO INC

    Revenue reached a record $7.0 million, up 22% year-over-year and 4% sequentially, driven by $6.1 million in pathology and $0.9 million in product revenue. Adjusted EBITDA turned positive at $0.4 million, reversing a $0.2 million loss in Q1-2026 and a $0.1 million loss in Q2-2025, supported by lower stock-based compensation. Cash flow from operations totaled $0.7 million, increasing the total cash balance to over $3 million at quarter-end without external financing. GAAP Net Loss narrowed to $(0.2) million from a $0.1 million Net Income in Q2-2025, while EBITDA (non-GAAP) declined to $0.0 million from $0.4 million in the prior year. Management characterized the quarter as a "healthy recovery" with record customer growth, though no specific forward guidance or M&A announcements were included in the summary.

  24. CNTNHealthcare

    Canton Strategic Holdings, Inc. — Second Quarter 2026 Earnings Summary

    CANTON STRATEGIC HOLDINGS INC

    Financial Results: Reported first-ever operating revenue of $1.49 million (primarily $1.30M from Locking-as-a-Service), resulting in a net loss of $19.25 million ($0.08/share) versus $1.43 million ($0.50/share) in Q2 2025; Adjusted EBITDA improved to $(820,449) from $(1.13M) in the prior year period. Balance Sheet & Liquidity: Cash and equivalents increased to $37.24 million from $12.01 million as of year-end 2025, while total stockholders' equity rose to $454.90 million; the company holds 3.71 billion Canton Coin units with a fair value of $523.35 million. Strategic Milestones: Completed the sale of legacy biotech subsidiary Gravitas Life Sciences for a $3.5 million note; secured approval for a full 15-unit Super Validator weight (active weight 0.5 as of June 30) with tranches scheduled to unlock through Q1 2028. Capital Allocation: Board approved a $50 million share repurchase program on June 11, 2026, though no shares were repurchased during the quarter.

  25. BYSIHealthcare

    BeyondSpring — Second Quarter 2026 Earnings Summary

    BEYONDSPRING INC

    Reported zero revenue for the quarter and six months ended June 30, 2026; net loss narrowed to $1.8 million (Q2) and $4.1 million (YTD) from $1.9 million and $4.5 million respectively in the prior year period. Cash and equivalents declined to $6.5 million as of June 30, 2026, from $12.6 million at year-end 2025, while shareholders' deficit widened to $36.0 million. Updated Phase 2 data for lead asset Plinabulin demonstrated a 58% two-year overall survival rate in metastatic NSCLC patients post-ICI therapy, supporting progression to the planned confirmatory DUBLIN-4 Phase 3 study. Executed leadership transition effective July 1, 2026, appointing Min Qiu as CEO and Na Li as CFO to prioritize DUBLIN-4 regulatory and operational preparations.